HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma #CTCL #DefendYourHealth #clinicaltrials ir.soligenix.com/2025-01-14-HyB…

We want to welcome Soligenix, Inc. to the DealFlow Events Microcap Conference January 28th and 30th, 2025, held at the Borgata Hotel Casino & Spa in Atlantic City, NJ. See their profile on B2i Digital at b2idigital.com/dealflow-micro… Soligenix, Inc. is a late-stage biopharmaceutical

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results $SNGX #DefendYourHealth lnkd.in/et-n7DDN

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants $SNGX #DefendYourHealth ir.soligenix.com/2025-03-25-Sol…

Interim results from our ongoing study show 75% of early-stage CTCL patients achieved Treatment Success after just 18 weeks with HyBryte™. Fast-acting, well-tolerated & promising for this rare cancer. #Biotech $SNGX #HyBryte #CancerResearch Learn more: ibn.fm/VUCS8

Soligenix $SNGX #HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By #FDA Funding 💥 Soligenix, Inc. is a late-stage #biopharma company focused on developing & commercializing products to treat rare diseases 👉 soligenix.com #cancer #ad #CTCL

Soligenix Issues Interim Results For CTCL Treatment Trial – 75% Response At 18 Weeks, 3 Patients Achieve Complete Response $SNGX benzinga.com/partner/biotec… via Benzinga

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results #defendyourhealth ir.soligenix.com/2025-05-09-Sol…

BioMedNewsBreaks — $SNGX HyBryte(TM) Delivers Strong Results in Rare Cancer Trial ibn.fm/VyQys

HyBryte study update with Dr. Ellen Kim #defendyourhealth #ctcl clfoundation.org/hybryte-flash

InvestorNewsBreaks – $SNGX Advances Clinical Programs, Eyes Critical Trial Results in 2025–2026 ibn.fm/rk4RC

BioMedNewsBreaks — $SNGX Advancing Novel Immunotherapy to Combat Antibiotic Resistance ibn.fm/3qtQA

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones #Defendyourhealth ir.soligenix.com/2025-07-08-Sol…

BioMedNewsBreaks — Targeting the Unmet: $SNGX Building Portfolio for Rare Conditions ibn.fm/UoSO3

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease $SNGX #DefendYourHealth ir.soligenix.com/2025-07-31-Bio…

$SNGX – Soligenix, Inc. Spotlighted in Editorial on Rare Disease Therapeutics ibn.fm/YAQLV

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results $sngx #defendyourhealth ir.soligenix.com/2025-08-18-FDA…

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference #defendyourhealth $SNGX ir.soligenix.com/2025-09-02-Sol…

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses #DefendYourHealth #SNGX ir.soligenix.com/2025-09-04-Sol…

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor #SNGX #DefendYourHealth ir.soligenix.com/2025-09-23-Sol…